ClinicalTrials.gg
CompletedNCT01820715Updated Aug 13, 2013

A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain

A Phase 1 interventional study of 600㎍ of DA-3030 Injection and Placebo in Diabetic Neuropathy, sponsored by Dong-A Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-08-13.

Sponsored by Dong-A Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Diabetic Neuropathies with a site in Korea, Republic of — none open to participants now, 1 under way, none of them phase 3. Diabetic Neuropathies · Korea, Republic of.

Enrollment
12th of 16
31 · median 75
Started
2010
with 2 others
Phase 1
3 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
1 of 16
Dong-A Pharmaceutical Co., Ltd.

Among the 16 studies in Diabetic Neuropathies with a site in Korea, Republic of, this one is the 12th largest by enrollment, is one of 3 that started in 2010, is one of 3 in phase 1, and was the 7th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

None of the 16 studies in Diabetic Neuropathies with a site in Korea, Republic of is open now. The open studies under Diabetic Neuropathies, anywhere →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Diabetic Neuropathies with a site in Korea, Republic of as a file.
02

Study summary

A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.

03

Conditions studied

  • Diabetic Neuropathy

Browse trials for

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20≤ Age ≤ 70
  • Diagnosed with Type I or Type II diabetes
  • ≤ 11%
  • Patients with diabetic neuropathic pain for at least 3 months
  • Patients corresponding to average pain level of 4 points or mor for 24 hours evaluated with 11-point Likert scale

Exclusion criteria

Exclusion Criteria:

  • Neuropathic pain due to other causes
  • Another stronger pain other than neuropathic pain
  • Abnormality in blood pressure, weight
  • Positive reaction in , or
  • A medical history of mental illness within 6 months
  • The grade of BDI(Beck Depression Inventory) exceeds 21 points
  • History of drug/alcohol abuse
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    600㎍ of DA-3030 Injection

    600㎍ of DA-3030 is injected once a day, for 5 continuous days.

    Drug: 600㎍ of DA-3030 Injection

  • Placebo comparator
    Placebo

    Placebo(a salin drip) is injected once a day, for 5 continuous days.

    Drug: Placebo

Interventions

  • Drug600㎍ of DA-3030 Injection
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Abnormal score of vital signs measured by following methods: two-sample t-test, Wilcoxon rank sum test, Paired t- test, Wilcoxon signed rank test, McNemar test, Chi-squared test, or/and Fisher's exact test

    Time frame: 12 Weeks

  2. Number of Subjects or Incidence with Adverse Events including Adverse Drug Event and Serious Adverse Event

    Time frame: 12 weeks

Secondary outcomes

  1. Average pain score

    Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)

    Time frame: 12 Weeks

  2. Most severe pain score

    Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)

    Time frame: 12 weeks

  3. overnight pain score

    Measuring how much the subject feels pain last night on a scale of one to ten (no pain - most severe pain)

    Time frame: 12 weeks

07

Study locations

1 site
  • Hanyang University Medical Center
    Seoul, 133-791, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010 and a primary completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2013
First posted
Mar 29, 2013
Start
Jun 2010
Primary completionActual
Apr 2013
Last update
Aug 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01820715
Responsible party
Sponsor
First posted
Mar 29, 2013
Start date
Jun 2010
Primary completion
Apr 2013
Last update
Aug 13, 2013

Study contacts

Yoo Heon Ahn, M.D., Ph.D.
principal investigator · Hanyang University
Bong Yeon Cha, M.D., Ph.D.
principal investigator · Seoul St. Mary's Hospital, The Catholic University of Korea
Kyung Soo Ko, M.D, Ph.D.
principal investigator · Inje University
Tae Sun Park, M.D., Ph.D.
principal investigator · Chonbuk National University Hospital
Young Soo Park, M.D.,Ph.D.
principal investigator · Hanyang University
Choon Hee Chung, M.D., Ph.D.
principal investigator · Wonju Christian Hospital
In Joo Kim, M.D., Ph.D.
principal investigator · Pusan National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion